It’s the Idorsia team’s passion for science that will translate our objectives into value creation for all our stakeholders. We are doing more with less in a highly productive environment where people enjoy their work. Our Idorsia professionals show up with energy, intellect and creativity.

Tausif (‘Tosh’) Butt

President and General Manager, Idorsia Pharmaceuticals US

Professional background: Tosh is a highly accomplished industry executive with more than 20 years of pharmaceutical leadership experience. Prior to joining Idorsia, Tosh served as Executive Vice President and Chief Operating Officer of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, which was acquired by Amgen in October 2022. At ChemoCentryx, Tosh built the commercial, market access, medical affairs, and tech ops functions, securing regulatory approval for the company’s first product in the US, Canada, EU, and Japan, and successfully launching the product in the rare disease space. Before that, Tosh was Senior Vice President of Latin America for AstraZeneca, where he led a team of more than 2,000 people, including five country presidents. Serving in leadership roles at AstraZeneca for more than six years – in marketing, sales, and market access – across the company’s primary care, biologics and vaccines, and oncology business lines, Tosh launched products in both primary and specialty care, including the company’s first biologic. Prior to this, he held several marketing and sales leadership roles in the United States, United Kingdom and France with GlaxoSmithKline and Sanofi.

Education: Tosh has a Bachelor’s degree in Pharmacy from the University of Brighton, UK, and an MSc in Management from Imperial College, University of London.

William Gileza

Vice President, Head of US Finance and Infrastructures

Professional background: Bill has enjoyed a 30-year adventure in the pharma industry in both the generic and specialty brand arenas. He has designed, implemented and led a full range of corporate financial functions including strategic and operational planning in fast-paced, growth environments, including strategic planning, budgeting and forecasting, operations analysis, pipeline selection and valuation, M&A valuation, accounting operations, performance tracking and reporting, corporate objectives programs, incentive compensation, as well as IT and procurement functions. Prior to joining Idorsia, Bill spent 11 years leading Lupin Pharma’s US finance operations in Baltimore, MD, as VP-Finance, where he oversaw the development of the finance and IT infrastructure from the ground up. Before Lupin, Bill spent 11 years with K-V Pharmaceutical in St. Louis, MO, where he rose to VP-Business Planning and led the business planning and analysis function covering branded, generic and specialty raw material divisions, with overall responsibility for budgeting and forecasting, M&A valuations, strategic planning and corporate objectives programs. Bill also spent 7 years building and leading the corporate accounting team for Schein Pharmaceuticals in Florham Park, NJ.

Education: Bill earned both his MBA and BS in Accounting & Economics from Clarkson University.

Kristine Freind

Vice President, Head of US Human Resources

Professional background: Kristine brings us almost 20 years of experience in the pharmaceutical and life sciences industries, 15 of which have been in the HR function. Prior to joining Idorsia in March 2023, she held senior positions at Trinseo, LLC, a spin-off from Dow Chemical, Radius Health, Inc., and AstraZeneca Pharmaceuticals, where she also held roles in Procurement and Commercial. Most recently, at Tinseo LLC, Kristine led an HR team responsible for supporting 1,000 employees in the US and Mexico and was the HR Business Partner to Supply Chain Services, Finance, Legal and Human Resources.

Throughout her career, Kristine has built responsive and insightful HR functions that act as true partners to business leaders and colleagues at all levels. She has collaborated closely with top leadership to develop and execute comprehensive HR plans and strategies, driven change management initiatives, and served as HR lead for mergers and acquisitions.

Education: Kristine received a B.A. in Biology from LaSalle University and an M.S. in Clinical Nutrition, concentrated in Human Biochemistry, from Drexel University. She is also a Registered Dietitian.

Michael Moye

Vice President, Head of US Marketing

Professional background: Michael brings 22 years of marketing, sales and leadership experience spanning the pharmaceutical, device and diagnostic industries. He has worked across primary care, specialty and rare therapeutic areas.  He joins us from Takeda Pharmaceuticals where he held the position of VP, US Hematology Franchise Lead and was responsible for a broad portfolio of rare disease products. Before his work at Shire and Takeda Michael was at Janssen Pharmaceuticals/J&J where he led the US Marketing efforts for Xarelto. Prior to that he was with Tethys Bioscience where he held the positions of Senior Marketing Director and Vice President of Sales and Operations. Previously he held US and global marketing positions at Merck, Schering- Plough and Millennium Pharmaceuticals.

Education: Michael holds a M.S. Ed. in Exercise Science and Wellness from Old Dominion University and B.S. in Sports Medicine from Marietta College.

Paul Varki

Vice President, US General Counsel, Head of Legal

Professional background: Paul brings 20 years of experience providing counsel in the pharmaceutical industry, at the Food and Drug Administration (FDA) and in private practice. He most recently served as Vice President, Legal, at Amarin Pharmaceuticals. He has led the legal and compliance functions as General Counsel at Braeburn Pharmaceuticals, and General Counsel and Chief Compliance Officer at Egalet Pharmaceuticals. Prior to that, he held various legal roles of increasing responsibility, including Assistant General Counsel, at GlaxoSmithKline. Paul also practiced FDA regulatory law at Reed Smith, and has served as Regulatory Counsel at the Center for Drug Evaluation and Research at FDA.

Education: Paul has a Juris Doctor from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary.

Brian Schlag

Vice President, Head of US Drug Regulatory Affairs

Professional background:  Brian has 20 years of experience in the pharmaceutical industry with expertise in regulatory affairs for innovative investigational and branded pharmaceuticals across multiple therapeutic areas, including neurology, psychiatry, cardiovascular, and orphan diseases.  He began his career at Wyeth Pharmaceuticals as a research scientist and transitioned into the regulatory affairs function.  He subsequently held regulatory affairs roles of increasing responsibility at Shire Pharmaceuticals and Actelion Pharmaceuticals, including responsibility for several flagship products and oversite of investigational and new drug applications.  When Actelion Pharmaceuticals was acquired by Janssen in 2017, Brian was appointed Vice President, Head of US Regulatory Affairs, leading all US regulatory activities for Idorsia, the newly formed company post-acquisition.

Education: Brian received his B.A. in Chemistry from Swarthmore College, M.A. in Neurosciences from Washington University in St. Louis, and an M.S. in Regulatory Affairs and Quality Assurance from Temple University.

Ajay Ahuja

Vice President, Head of US Medical Affairs

Professional background:  Dr. Ahuja is a cardiologist who has over two decades of experience as biopharmaceutical executive with a unique combination of business and scientific expertise.  His leadership roles in Medical Affairs include serving as the Global Head of Medical Affairs for Allergan and Head of Medical Affairs for Hospira, launching multiple biologic compounds in distinct markets across the globe.  He has also worked in Vice President roles at GlaxoSmithKline, Pfizer and Takeda Pharmaceuticals.  Prior to that, he progressed through US and Global roles in Marketing, Strategy, Commercial Operations, and Business Development with Novartis and Tepha, Inc. earlier in his business career, while also working as an attending physician at Boston Children’s Hospital, Harvard Medical School.

Education:  Dr. Ahuja earned a B.S. degree from Duke University, an M.D. degree from Washington University School of Medicine, and an M.B.A. from Harvard Business School.

Madeline Scherwitzky

Vice President, Head of US Compliance

Professional Background: Maddy brings nearly 15 years of compliance experience in the pharmaceutical and biotech industries. Prior to joining Idorsia in February 2023, she held senior positions at Biohaven Pharmaceuticals and Assertio Therapeutics (previously Zyla Life Sciences US and Egalet US). She was also the owner and president of MPS Consulting, LLC, where she consulted with multiple newly or pre-commercialized organizations on the development and launch of a compliance solution befitting strategic direction and size. Prior to this Maddy held roles of increasing responsibility as a consultant to the pharmaceutical industry at KPMG and Compliance Implementation Services (CIS). Throughout her career, she has been responsible for the identification and assessment of risk, and the design and implementation of compliance programs, including development of compliance policies, business rules and related training, as well as compliance monitoring activities across all aspects of the business.

Education: Maddy received her B.A. in English and Economics & Accounting from the College of the Holy Cross in Worcester, MA, and is a Certified Public Accountant licensed in PA.